-
公开(公告)号：US11555742B2
公开(公告)日：2023-01-17
申请号：US17271826
申请日：2019-09-04
发明人： Zhenguo Wu , Haishan Zeng , Jianhua Zhao , Liwei Jiang
摘要： Systems for confocal Raman spectroscopy of points of interest or regions of interest with concurrent imaging are disclosed. The imaging may be used for real time selection of points of interest or regions of interest for Raman spectroscopy and to monitor for unwanted motions of a sample while Raman spectra are acquired. Disclosed embodiments apply Reflectance confocal microscopy (RCM) in a confocal Raman spectroscopy system. A single laser may be used as a light source for both RCM and micro-Raman spectroscopy. A Faraday optical isolator may be applied to extract RCM signals for imaging Systems as described herein have example application for ex vivo sample and in vivo skin measurement.
-
公开(公告)号：US20220227883A1
公开(公告)日：2022-07-21
申请号：US17613698
申请日：2020-05-26
发明人： Robert HOLT , Craig RIVE , Simon TURCOTTE
IPC分类号： C07K16/32 , C07K14/725 , A61P35/00 , G01N33/574 , C12N5/09 , G01N33/50
摘要： An antigen targeting agent is provided. The antigen targeting agent binds to a mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) protein having a missense mutation at position 12 when a peptide incorporating the missense mutation is presented by an HLA-A*02 molecule. The missense mutation at position 12 of the KRAS protein may be G12D, G12V or G12C. The antigen targeting agents can be used diagnostically or for immunotherapy.
-
公开(公告)号：US20220160908A1
公开(公告)日：2022-05-26
申请号：US17441125
申请日：2019-09-25
申请人： The University Of British Columbia , Provincial Health Services Authority , Abdera Therapeutics Inc.
发明人： Lee Lee Lily LI , Chris ORVIG , Francois BENARD , Kuo-Shyan LIN , Julie Marie ROUSSEAU , Ismael SAMUDIO
IPC分类号： A61K51/10 , A61K51/04 , C07D213/79
摘要： A chelating agent having the general formula (I) is provided (I) Metal chelates and constructs for carrying out targeted radionuclide therapy incorporating such chelating agents are provided. Methods of making and using the chelating agent, metal chelates and constructs for carrying out targeted radionuclide therapy, as well as diagnostic and therapeutic methods using such constructs, are provided.
-
公开(公告)号：US20220062446A1
公开(公告)日：2022-03-03
申请号：US17415649
申请日：2019-12-18
发明人： David Perrin , Aron Roxin , Mathieu Lepage , Sungjoon Huh , Zhibo Liu , Rajaguru Kandasamy , Francois Benard , Kuo-Shyan Lin , Hsiou-Ting Kuo , Chengcheng Zhang
摘要： A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F/18F exchange or a precursor thereof; and optionally a cell-targeting domain.
-
公开(公告)号：US11123509B2
公开(公告)日：2021-09-21
申请号：US15594381
申请日：2017-05-12
发明人： F. Robert Purdy
摘要： Disclosed is a respiratory treatment apparatus that may be especially helpful for pediatric patients, though it may be useful for patients of all ages. In one embodiment, the apparatus comprises an endotracheal tube that is physically coupled to a bronchial blocker in a non-concentric fashion. In another embodiment, the apparatus comprises an endotracheal tube that is physically coupled to a steering balloon apparatus. The endotracheal tube, bronchial blocker, and/or steering balloon apparatus may be non-unitary components that are attachable to one another with one or more attachment structures, and once physically coupled, may be put to use. The endotracheal tube and bronchial blocker and steering balloon apparatus may be selected from a plurality of endotracheal tubes and bronchial blockers and steering balloon apparatus, to create an assembled apparatus that meets the needs of the patient.
-
公开(公告)号：US20210205483A1
公开(公告)日：2021-07-08
申请号：US17057506
申请日：2019-05-23
摘要： A compound is provided comprising a melanocortin 1 receptor (MC1R) targeting peptide (MC1RTP), a radiolabeling group, and a linker joining the MC1RTP to the radiolabeling group. The MC1RTP is linear or cyclized, and comprises a sequence of Formula I or Formula II: Xaa1-Xaa2a-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7a (I) or Xaa1-Xaa2b-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7b (II). Xaa1 is L-/D-Nle, L-/D-Nle, L-/D-Ala, L-/D-Leu, L-/D-Ile, D-Ile, L-/D-Cys, L-/D-Met, L-/D-Phe, L-/D-Trp, L-/D-Val, L-/D-Nal, L-/D-2-Nal, Gly, L-/D-α-aminobutryic acid, L-/D-norvaline, or L-/D-homonorleucine. Xaa2a and Xaa7b are L-/D-Cys, L-/D-Asp, L-/D-Glu, L-/D-2-Aad, L-/D-3-Aad, L-/D-Pra, L-/D-Hpg, or L-/D-Bpg. Xaa2b and Xaa7a are L-/D-Cys, L-/D-Lys, L-/D-Orn, L-/D-Dab, L-/D-Dap, L-/D-Lys(N3), L-/D-Orn(N3), L-/D-Dab(N3), L-/D-Dap(N3), L-/D-2-(5′-azidopentyl)alanine, or L-/D-2-(6′-azidohexyl)alanine. Xaa3 is L-/D-His, Pro, beta-(1,2,3-triazol-4-yl)-L-alanine, beta-(1,2,3-triazol-4-yl)-D-alanine, 1,2,4-triazole-3-alanine, or 1,2,4-triazole-3-D-N alanine. Xaa4 is L-/D-Phe, L-/D-2-Nal, L-/D-Phe(4-F), L-/D-Phe(4-Cl), L-/D-Phe(4-Br), L-/D-Phe(4-I), L-/D-Phe(4-NH2), or L-/D-Phe(4-NO2). Xaa5 is L-/D-Arg, L-/D-hArg), Leu, L-/D-Agb, or L-/D-Agp. Xaa6 is L-/D-Trp, L-/D-Phe, L-/D-Trp(5-Br), L-/D-Trp(5-OCH3), L-/D-Trp(6-F), L-/D-Trp(5-OH) or L-/D-Trp(CHO). One or more amino acid residues of the MC1RTP is alpha N-methylated, wherein 1, 2, 3 or 4 of Xaa3, Xaa5, Xaa6 and Xaa7a is alpha N-methylated or wherein 1, 2, 3 or 4 of Xaa3, Xaa5, Xaa6 and Xaa7b is alpha N-methylated. The linker comprises an albumin-binding group.
-
公开(公告)号：US20240342321A1
公开(公告)日：2024-10-17
申请号：US18756500
申请日：2024-06-27
发明人： François BÉNARD , Kuo-Shyan LIN , Zhengxing ZHANG , Daniel KWON , David PERRIN , Mijhajlo TODOROVIC , Jerome LOZADA , Lee Lee LI
CPC分类号： A61K51/088 , A61P35/00 , C07K7/64
摘要： The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.
-
公开(公告)号：US12059284B2
公开(公告)日：2024-08-13
申请号：US17597214
申请日：2020-06-23
发明人： Peng Huang , Yuliang Li , Stephen Lam
CPC分类号： A61B6/5211 , A61B6/03 , A61B6/5229 , G06N3/045 , G06T7/0016 , G16H50/20 , G06T2207/30064
摘要： A device may obtain first information relating to one or more first lung nodules identified in first imaging of a chest of a patient and second information relating to one or more second lung nodules identified in second imaging of the chest of the patient. The device may provide the first information and the second information to a machine learning model. The device may determine, using the machine learning model, a risk of lung cancer associated with the patient based on an elapsed time between performance of the first imaging and the second imaging and differences between the first information and the second information. The risk of lung cancer may have an inverse correlation to the elapsed time and a direct correlation to the differences. The device may perform one or more actions based on the risk of lung cancer that is determined
-
49.发明公开公开(公告)号：US20240239790A1
公开(公告)日：2024-07-18
申请号：US18279379
申请日：2022-03-10
发明人： Stephen Paul Arns , Tom Han Hsiao Hsieh , Fahimeh S. Shidmoossavee , Jason Samuel Tan , Leanna Yee , Jay John Paquette , James Brian Jaquith , Simon Andrew Osborne , Ela Smiljanic-Hurley , Callum Hamby , Elliott Smyth , Martin Ambler , Andrew I. Minchinton , Alastair H. Kyle , Jennifer H.E. Baker
IPC分类号： C07D471/04 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K45/06 , A61K48/00 , A61P35/00 , C07D519/00 , C12N9/22 , C12N15/11 , C12N15/63
CPC分类号： C07D471/04 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K45/06 , A61K48/005 , A61P35/00 , C07D519/00 , C12N9/22 , C12N15/111 , C12N15/63 , C12N2310/20
摘要： The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Certain compounds of the present disclosure are in the form of prodrugs that release the DNA-PK inhibitor in hypoxic tissue such as is known to occur in cancers. Aspects of the present disclosure also include methods of using the compounds for repairing a DNA break in a target genomic region or for modifying expression of one or more genes or proteins. Compounds provided are of formula: (II)
-
公开(公告)号：US11919874B2
公开(公告)日：2024-03-05
申请号：US17404589
申请日：2021-08-17
发明人： Raymond J. Andersen , Marianne Dorothy Sadar , Kunzhong Jian , Nasrin R. Mawji , Jun Wang , Carmen Adriana Banuelos , Yu-Chi Yang
IPC分类号： C07D295/088 , A61K31/09 , A61K31/10 , A61K31/145 , A61K31/4164 , A61K31/5375 , A61K45/06 , C07C43/23 , C07C69/28 , C07C233/18 , C07C311/04 , C07C311/51 , C07C317/18 , C07C317/22 , C07C317/28 , C07D233/60
CPC分类号： C07D295/088 , A61K31/09 , A61K31/10 , A61K31/145 , A61K31/4164 , A61K31/5375 , A61K45/06 , C07C43/23 , C07C69/28 , C07C233/18 , C07C311/04 , C07C311/51 , C07C317/18 , C07C317/22 , C07C317/28 , C07D233/60
摘要： Compounds having a structure of Formula I:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.023 秒)
